These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34225766)

  • 1. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.
    Wang C; Shi F; Liu Y; Zhang Y; Dong L; Li X; Tong C; Wang Y; Su L; Nie J; Han W
    J Hematol Oncol; 2021 Jul; 14(1):106. PubMed ID: 34225766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
    Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
    J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
    Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
    Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.
    Landsburg DJ; Nasta SD; Svoboda J; Gerson JN; Schuster SJ; Barta SK; Chong EA; Difilippo H; Weber E; Cunningham K; Catania C; Garfall AL; Stadtmauer EA; Frey NV; Porter DL
    Transplant Cell Ther; 2023 Aug; 29(8):495-503. PubMed ID: 37211154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
    Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
    Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
    Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
    Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
    Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
    Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
    Chong EA; Alanio C; Svoboda J; Nasta SD; Landsburg DJ; Lacey SF; Ruella M; Bhattacharyya S; Wherry EJ; Schuster SJ
    Blood; 2022 Feb; 139(7):1026-1038. PubMed ID: 34496014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment response to PD-1 blockade therapy in a patient with DLBCL relapsed after anti-CD19 chimeric antigen receptor T cell treatment.
    Zhang L; Zhang W; Zhou D
    Ann Hematol; 2021 Jan; 100(1):289-291. PubMed ID: 32335701
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.
    Negishi S; Girsch JH; Siegler EL; Bezerra ED; Miyao K; Sakemura RL
    Front Pediatr; 2023; 11():1305657. PubMed ID: 38283399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
    Zhang Y; Patel RP; Kim KH; Cho H; Jo JC; Jeong SH; Oh SY; Choi YS; Kim SH; Lee JH; Angelos M; Guruprasad P; Cohen I; Ugwuanyi O; Lee YG; Pajarillo R; Cho JH; Carturan A; Paruzzo L; Ghilardi G; Wang M; Kim S; Kim SM; Lee HJ; Park JH; Cui L; Lee TB; Hwang IS; Lee YH; Lee YJ; Porazzi P; Liu D; Lee Y; Kim JH; Lee JS; Yoon DH; Chung J; Ruella M
    Mol Cancer; 2023 Dec; 22(1):200. PubMed ID: 38066564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.
    Caballero AC; Escribà-Garcia L; Alvarez-Fernández C; Briones J
    Front Immunol; 2022; 13():904497. PubMed ID: 35874685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
    Sigmund AM; Denlinger N; Huang Y; Bond D; Voorhees T; Bajwa A; Elder P; Brammer JE; Saad A; Penza S; Vasu S; de Lima M; Jaglowski S; Kittai AS
    Transplant Cell Ther; 2022 Jun; 28(6):342.e1-342.e5. PubMed ID: 35248778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
    Kinoshita H; Bollard CM; Toner K
    Semin Hematol; 2023 Nov; 60(5):329-337. PubMed ID: 38336529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
    Du J; Zhang Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
    Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
    N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.